Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region – Global Forecast to 2030

1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 42 1.3.2 REGIONAL SCOPE 43 1.3.3 INCLUSIONS & EXCLUSIONS 43 1.3.4 YEARS CONSIDERED 45 1.4 CURRENCY CONSIDERED 45 1.5 LIMITATIONS 46 1.6 STAKEHOLDERS 46 1.7 SUMMARY OF CHANGES 47 2 EXECUTIVE SUMMARY 49 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 49 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 51 2.3 DISRUPTIVE TRENDS IN NUCLEAR MEDICINE MARKET 52 2.4 HIGH-GROWTH SEGMENTS 53 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 54 3 PREMIUM INSIGHTS 55 3.1 NUCLEAR MEDICINE MARKET OVERVIEW 55 3.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE & COUNTRY 56 3.3 NUCLEAR MEDICINE MARKET: GEOGRAPHIC SNAPSHOT 56 3.4 NUCLEAR MEDICINE MARKET: DEVELOPED VS. EMERGING ECONOMIES 57 4 MARKET OVERVIEW 58 4.1 INTRODUCTION 58 4.2 MARKET DYNAMICS 59 4.2.1 DRIVERS 59 4.2.1.1 Increasing incidence and prevalence of target conditions 59 4.2.1.2 Rapid expansion of radioligand & targeted radionuclide therapy 60 4.2.1.3 Strategic entry of large pharma & capital inflows 61 4.2.1.4 Initiatives to reduce demand and supply gap of Mo-99 62 4.2.2 RESTRAINTS 64 4.2.2.1 Short half-life of radiopharmaceuticals 64 4.2.2.2 Structural isotope supply fragility 66   4.2.3 OPPORTUNITIES 67 4.2.3.1 Development of alpha-radioimmunotherapy-based targeted cancer treatments 67 4.2.3.2 Use of radiopharmaceuticals in neurological applications 68 4.2.3.3 Growth opportunities in emerging economies and expanding PET Infrastructure 69 4.2.4 CHALLENGES 71 4.2.4.1 High capital intensity of nuclear medicine infrastructure and hospital budget cuts 71 4.2.4.2 Workforce shortage in nuclear medicine 72 4.3 UNMET NEEDS & WHITE SPACES 73 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 73 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74 5 INDUSTRY TRENDS 76 5.1 PORTER’S FIVE FORCES ANALYSIS 76 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 77 5.1.2 BARGAINING POWER OF SUPPLIERS 77 5.1.3 BARGAINING POWER OF BUYERS 77 5.1.4 THREAT OF SUBSTITUTES 77 5.1.5 THREAT OF NEW ENTRANTS 78 5.2 MACROECONOMIC INDICATORS 78 5.2.1 INTRODUCTION 78 5.2.2 GDP TRENDS & FORECAST 78 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 79 5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY 80 5.3 VALUE CHAIN ANALYSIS 80 5.4 ECOSYSTEM ANALYSIS 82 5.5 PRICING ANALYSIS 85 5.5.1 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024 85 5.5.2 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY REGION, 2024 86 5.6 TRADE ANALYSIS 87 5.6.1 IMPORT SCENARIO FOR HS CODE 2844 87 5.6.2 EXPORT SCENARIO FOR HS CODE 2844 88 5.6.3 IMPORT SCENARIO FOR HS CODE 3002 89 5.6.4 EXPORT SCENARIO FOR HS CODE 3002 89 5.7 KEY CONFERENCES & EVENTS, 2026–2027 90 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 5.9 INVESTMENT & FUNDING SCENARIO 92 5.10 CASE STUDY ANALYSIS 93 5.11 IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE MARKET 95 5.11.1 INTRODUCTION 95 5.11.2 KEY TARIFF RATES 96 5.11.3 PRICE IMPACT ANALYSIS 97 5.11.4 IMPACT ON COUNTRY/REGION 97 5.11.4.1 US 97 5.11.4.2 Europe 97 5.11.4.3 Asia Pacific 98 5.11.5 IMPACT ON END-USE INDUSTRIES 98 5.11.5.1 Hospitals 98 5.11.5.2 Diagnostic & imaging centers 98 5.11.5.3 Research & academic institutes 99 6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION 100 6.1 KEY EMERGING TECHNOLOGIES 100 6.1.1 NEXT-GENERATION RADIOLIGAND THERAPY & THERANOSTICS 100 6.1.2 RADIOISOTOPE PRODUCTION TECHNOLOGIES 100 6.1.3 HIGH-SPECIFIC-ACTIVITY RADIOLABELING AND CHELATION CHEMISTRY 101 6.1.4 GMP HOT-CELL MANUFACTURING & RADIOPHARMACEUTICAL QUALITY CONTROL 101 6.1.5 COLD KIT & GENERATOR TECHNOLOGIES 102 6.1.6 DECENTRALIZED ISOTOPE PRODUCTION & ADVANCED RADIOPHARMACY SYSTEMS 103 6.2 COMPLEMENTARY TECHNOLOGIES 103 6.2.1 AUTOMATED RADIOTRACER SYNTHESIS & DISPENSING SYSTEMS 103 6.2.2 DOSIMETRY & TREATMENT PLANNING TECHNOLOGIES 103 6.3 ADJACENT TECHNOLOGIES 104 6.3.1 TARGET DISCOVERY & RADIOLIGAND DESIGN PLATFORMS 104 6.3.2 INTEGRATED THERANOSTIC WORKFLOWS & DATA PLATFORMS 105 6.3.3 AI-ENABLED QUANTITATIVE IMAGING & WORKFLOW AUTOMATION 105 6.4 TECHNOLOGY/PRODUCT ROADMAP 105 6.5 PATENT ANALYSIS 106 6.5.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE MARKET 106 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 107 6.6 FUTURE APPLICATIONS 109 6.6.1 PRECISION ONCOLOGY & THERANOSTICS EXPANSION 110 6.6.2 PERSONALIZED RADIONUCLIDE THERAPY USING DOSIMETRY-GUIDED DOSING 110 6.6.3 EARLY DISEASE DETECTION & RISK STRATIFICATION 111 6.6.4 NEURODEGENERATIVE & NEUROINFLAMMATORY DISORDERS 111 6.6.5 INFLAMMATION, INFECTION, AND IMMUNE SYSTEM IMAGING 111 6.7 IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE MARKET 112 6.7.1 INTRODUCTION 112 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN NUCLEAR MEDICINE MARKET 113   6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 115 6.7.3.1 Clinical validation of AI-enabled standardization and workflow efficiency in PSMA PET imaging for prostate cancer 115 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 116 6.7.4.1 Radiopharmacy, manufacturing, and quality operations 116 6.7.4.2 Clinical imaging, dosimetry, and treatment planning infrastructure 116 6.7.4.3 Hospital systems, regulatory compliance, and theranostic data platforms 117 6.7.5 USER READINESS AND IMPACT ASSESSMENT 117 6.7.5.1 User readiness 117 6.7.5.1.1 User A: Hospitals 117 6.7.5.1.2 User B: Diagnostic & imaging centers 117 6.7.5.2 Impact assessment 118 6.7.5.2.1 User A: Hospitals 118 6.7.5.2.1.1 Implementation 118 6.7.5.2.1.2 Impact 118 6.7.5.2.2 User B: Diagnostic & imaging centers 118 6.7.5.2.2.1 Implementation 118 6.7.5.2.2.2 Impact 118 7 REGULATORY LANDSCAPE 119 7.1 REGIONAL REGULATIONS & COMPLIANCE 119 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121 7.1.2 REGULATORY FRAMEWORK 127 7.1.2.1 North America 127 7.1.2.2 Europe 130 7.1.2.3 Asia Pacific 133 7.1.2.4 Latin America 135 7.1.2.5 Middle East & Africa 135 7.1.3 INDUSTRY STANDARDS 136 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 138 8.1 INTRODUCTION 138 8.2 DECISION-MAKING PROCESS 138 8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 139 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 139 8.3.2 BUYING CRITERIA 140 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 141 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 142 8.5.1 UNMET NEEDS 142 8.5.2 END-USER EXPECTATIONS 144 8.6 MARKET PROFITABILITY 145 9 NUCLEAR MEDICINE MARKET, BY TYPE 146 9.1 INTRODUCTION 147 9.2 DIAGNOSTIC NUCLEAR MEDICINE 147 9.2.1 SPECT RADIOPHARMACEUTICALS 148 9.2.1.1 Tc-99m 151 9.2.1.1.1 Dominant role of Tc-99m in SPECT to boost market growth 151 9.2.1.2 I-123 152 9.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive demand 152 9.2.1.3 Tl-201 153 9.2.1.3.1 Most commonly used substitute for Tc-99m in cardiac stress tests to support market growth 153 9.2.1.4 Ga-67 154 9.2.1.4.1 Long half-life of Ga-67 to facilitate easy sales and distribution 154 9.2.1.5 Other SPECT radiopharmaceuticals 155 9.2.2 PET RADIOPHARMACEUTICALS 156 9.2.2.1 F-18 157 9.2.2.1.1 Advantages such as highly accurate, metabolism-based cancer imaging to boost demand 157 9.2.2.2 Rb-82 158 9.2.2.2.1 High accuracy offered by Rb-82 isotopes to support market growth 158 9.2.2.3 Other PET radiopharmaceuticals 159 9.3 THERAPEUTIC NUCLEAR MEDICINE 160 9.3.1 ALPHA EMITTERS 161 9.3.1.1 Ra-223 162 9.3.1.1.1 Rising metastatic prostate cancer burden and demand for bone-targeted, outpatient alpha therapy to drive adoption 162 9.3.2 BETA EMITTERS 163 9.3.2.1 I-131 164 9.3.2.1.1 I-131 to account for largest share of beta emitters market during forecast period 164 9.3.2.2 Y-90 165 9.3.2.2.1 Rising incidence of liver cancers and hepatocellular carcinoma to propel growth 165 9.3.2.3 Sm-153 165 9.3.2.3.1 Increasing incidence of bone metastasis to drive market 165 9.3.2.4 Lu-177 166 9.3.2.4.1 Rising cancer burden and expanding PRRT adoption to fuel growth 166 9.3.2.5 Other beta emitters 167   9.3.3 BRACHYTHERAPY ISOTOPES 168 9.3.3.1 I-125 169 9.3.3.1.1 I-125 to account for largest share of brachytherapy isotopes market 169 9.3.3.2 Ir-192 170 9.3.3.2.1 Precise, high-dose brachytherapy across multiple cancers to propel market 170 9.3.3.3 Pd-103 171 9.3.3.3.1 Ability to make brachytherapy permanent implant seeds for early-stage prostate cancer to drive adoption 171 9.3.3.4 Cs-131 172 9.3.3.4.1 Growing use of Cs-131 in gynecological applications to aid growth 172 9.3.3.5 Other brachytherapy isotopes 172 10 NUCLEAR MEDICINE MARKET, BY APPLICATION 174 10.1 INTRODUCTION 175 10.2 DIAGNOSTIC APPLICATIONS 175 10.2.1 SPECT APPLICATIONS 176 10.2.1.1 Cardiology 178 10.2.1.1.1 Rising global cardiovascular disease burden and expanding, evidence-backed cardiology applications to drive growth 178 10.2.1.2 Bone scans 179 10.2.1.2.1 High precision of SPECT to boost adoption of bone scans 179 10.2.1.3 Thyroid 180 10.2.1.3.1 Rising demand for combination SPECT/CT therapy to drive market growth 180 10.2.1.4 Pulmonary scans 181 10.2.1.4.1 High accuracy and sensitivity of SPECT/CT pulmonary imaging to boost market 181 10.2.1.5 Other SPECT applications 182 10.2.2 PET APPLICATIONS 183 10.2.2.1 Oncology 184 10.2.2.1.1 Increasing incidence of cancer to fuel market growth 184 10.2.2.2 Cardiology 186 10.2.2.2.1 Growing preference for FDG in cardiac imaging to propel market 186 10.2.2.3 Neurology 187 10.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson’s disease to increase adoption of PET imaging 187 10.2.2.4 Other PET applications 188   10.3 THERAPEUTIC APPLICATIONS 189 10.3.1 THYROID INDICATIONS 190 10.3.1.1 Increasing prevalence of thyroid disorders to boost market 190 10.3.2 BONE METASTASIS 191 10.3.2.1 Introduction of novel therapies for bone metastasis to positively impact market growth 191 10.3.3 ENDOCRINE TUMORS 192 10.3.3.1 US to dominate therapeutic nuclear medicine market for endocrine tumor applications 192 10.3.4 LYMPHOMA 193 10.3.4.1 Development of new isotopes for treatment of lymphoma to present huge growth opportunities 193 10.3.5 OTHER THERAPEUTIC APPLICATIONS 194 11 NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT 195 11.1 INTRODUCTION 196 11.2 DIAGNOSTIC PROCEDURES 197 11.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH 197 11.3 THERAPEUTIC PROCEDURES 198 11.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH 198 12 NUCLEAR MEDICINE MARKET, BY END USER 200 12.1 INTRODUCTION 201 12.2 HOSPITALS 202 12.2.1 GROWING VOLUME OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET GROWTH 202 12.3 DIAGNOSTIC & IMAGING CENTERS 203 12.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 203 12.4 ACADEMIC & RESEARCH INSTITUTES 204 12.4.1 INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH 204 12.5 OTHER END USERS 206 13 NUCLEAR MEDICINE MARKET, BY REGION 207 13.1 INTRODUCTION 208 13.2 NORTH AMERICA 209 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 210 13.2.2 US 218 13.2.2.1 US to dominate North American nuclear medicine market during forecast period 218   13.2.3 CANADA 226 13.2.3.1 Increasing initiatives for medical isotope development to support market growth 226 13.3 EUROPE 233 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 234 13.3.2 GERMANY 242 13.3.2.1 Well-established healthcare system to drive market growth 242 13.3.3 FRANCE 250 13.3.3.1 Rising incidence of diseases such as cancer, Alzheimer’s, and Parkinson’s disease to favor market growth 250 13.3.4 UK 258 13.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth 258 13.3.5 ITALY 265 13.3.5.1 Aging demographics, high procedure volumes, increasing cancer incidence, and domestic isotope self-sufficiency to fuel growth 265 13.3.6 SPAIN 273 13.3.6.1 Rising disease prevalence, regulatory modernization, and targeted radioligand expansion to create supportive environment 273 13.3.7 REST OF EUROPE 280 13.4 ASIA PACIFIC 288 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 288 13.4.2 JAPAN 298 13.4.2.1 Japan to dominate APAC nuclear medicine market 298 13.4.3 CHINA 306 13.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market 306 13.4.4 INDIA 314 13.4.4.1 Rising cancer and cardiovascular disease burden and rapid expansion of nuclear medicine infrastructure to boost market 314 13.4.5 SOUTH KOREA 321 13.4.5.1 Accelerating PET utilization and maturing domestic RPT innovation ecosystem to augment market 321 13.4.6 AUSTRALIA 328 13.4.6.1 Rising cancer prevalence, high PET penetration, and growing domestic isotope production to support growth 328 13.4.7 REST OF ASIA PACIFIC 335 13.5 LATIN AMERICA 342 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 342 13.5.2 BRAZIL 349 13.5.2.1 Rising cancer incidence and expanding imaging infrastructure to drive market 349 13.5.3 MEXICO 356 13.5.3.1 Rising cancer and cardiovascular disease burden and expanding private-sector PET access to drive market 356 13.5.4 REST OF LATIN AMERICA 362 13.6 MIDDLE EAST & AFRICA 368 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 368 13.6.2 GCC COUNTRIES 375 13.6.2.1 Growing healthcare needs and favorable government support to boost market 375 13.6.3 REST OF MIDDLE EAST & AFRICA 380 14 COMPETITIVE LANDSCAPE 387 14.1 OVERVIEW 387 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 387 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET 388 14.3 REVENUE ANALYSIS, 2020–2024 391 14.4 MARKET SHARE ANALYSIS, 2024 392 14.5 BRAND/PRODUCT COMPARISON 396 14.6 COMPANY VALUATION & FINANCIAL METRICS 397 14.6.1 FINANCIAL METRICS 397 14.6.2 COMPANY VALUATION 397 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 398 14.7.1 STARS 398 14.7.2 EMERGING LEADERS 398 14.7.3 PERVASIVE PLAYERS 398 14.7.4 PARTICIPANTS 399 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 400 14.7.5.1 Company footprint 400 14.7.5.2 Region footprint 401 14.7.5.3 Type footprint 402 14.7.5.4 Application footprint 403 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 404 14.8.1 PROGRESSIVE COMPANIES 404 14.8.2 RESPONSIVE COMPANIES 404 14.8.3 DYNAMIC COMPANIES 404 14.8.4 STARTING BLOCKS 404 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 406 14.8.5.1 Detailed list of key startups/SMEs 406 14.8.5.2 Competitive benchmarking of startups/SMEs 406 14.9 COMPETITIVE SCENARIO 408 14.9.1 PRODUCT APPROVALS 408 14.9.2 DEALS 410 14.9.3 EXPANSIONS 412 14.9.4 OTHER DEVELOPMENTS 413 15 COMPANY PROFILES 414 15.1 KEY PLAYERS 414 15.1.1 NOVARTIS AG 414 15.1.1.1 Business overview 414 15.1.1.2 Products offered 415 15.1.1.3 Recent developments 416 15.1.1.3.1 Product approvals 416 15.1.1.3.2 Deals 417 15.1.1.3.3 Expansions 418 15.1.1.4 MnM view 419 15.1.1.4.1 Right to win 419 15.1.1.4.2 Strategic choices 420 15.1.1.4.3 Weaknesses & competitive threats 420 15.1.2 LANTHEUS HOLDINGS, INC. 421 15.1.2.1 Business overview 421 15.1.2.2 Products offered 422 15.1.2.3 Recent developments 423 15.1.2.3.1 Deals 423 15.1.2.4 MnM view 424 15.1.2.4.1 Right to win 424 15.1.2.4.2 Strategic choices 424 15.1.2.4.3 Weaknesses & competitive threats 424 15.1.3 GE HEALTHCARE 425 15.1.3.1 Business overview 425 15.1.3.2 Products offered 426 15.1.3.3 Recent developments 427 15.1.3.3.1 Product approvals 427 15.1.3.3.2 Deals 427 15.1.3.3.3 Expansions 429 15.1.3.3.4 Other developments 429 15.1.3.4 MnM view 430 15.1.3.4.1 Right to win 430 15.1.3.4.2 Strategic choices 430 15.1.3.4.3 Weaknesses & competitive threats 430 15.1.4 CURIUM 431 15.1.4.1 Business overview 431 15.1.4.2 Products offered 431 15.1.4.3 Recent developments 435 15.1.4.3.1 Product approvals & enhancements 435 15.1.4.3.2 Deals 436 15.1.4.3.3 Expansions 438 15.1.4.3.4 Other developments 438 15.1.4.4 MnM view 438 15.1.4.4.1 Right to win 438 15.1.4.4.2 Strategic choices 438 15.1.4.4.3 Weaknesses & competitive threats 439 15.1.5 TELIX PHARMACEUTICALS LIMITED 440 15.1.5.1 Business overview 440 15.1.5.2 Products offered 441 15.1.5.3 Recent developments 442 15.1.5.3.1 Product approvals 442 15.1.5.3.2 Deals 443 15.1.5.3.3 Other developments 444 15.1.5.4 MnM view 444 15.1.5.4.1 Right to win 444 15.1.5.4.2 Strategic choices 444 15.1.5.4.3 Weaknesses & competitive threats 445 15.1.6 SIEMENS HEALTHINEERS 446 15.1.6.1 Business overview 446 15.1.6.2 Products offered 447 15.1.6.3 Recent developments 448 15.1.6.3.1 Deals 448 15.1.6.3.2 Other developments 448 15.1.7 CHINA ISOTOPE & RADIATION CORPORATION 449 15.1.7.1 Business overview 449 15.1.7.2 Products offered 450 15.1.7.3 Recent developments 451 15.1.7.3.1 Other developments 451 15.1.8 BAYER AG 452 15.1.8.1 Business overview 452 15.1.8.2 Products offered 453 15.1.8.3 Recent developments 454 15.1.8.3.1 Deals 454 15.1.9 BRACCO IMAGING S.P.A. 455 15.1.9.1 Business overview 455 15.1.9.2 Products offered 455 15.1.9.3 Recent developments 456 15.1.9.3.1 Product approvals 456 15.1.9.3.2 Deals 456 15.1.9.3.3 Other developments 457 15.1.10 CARDINAL HEALTH 458 15.1.10.1 Business overview 458 15.1.10.2 Products offered 459   15.1.10.3 Recent developments 462 15.1.10.3.1 Deals 462 15.1.11 JUBILANT PHARMOVA LIMITED 463 15.1.11.1 Business overview 463 15.1.11.2 Products offered 464 15.1.11.3 Recent developments 466 15.1.11.3.1 Product approvals 466 15.1.11.3.2 Deals 466 15.1.11.3.3 Other developments 467 15.1.12 ELI LILLY AND COMPANY 468 15.1.12.1 Business overview 468 15.1.12.2 Products offered 469 15.1.12.3 Recent developments 470 15.1.12.3.1 Deals 470 15.1.12.3.2 Other developments 471 15.1.13 BWXT MEDICAL LTD. 472 15.1.13.1 Business overview 472 15.1.13.2 Products offered 472 15.1.13.3 Recent developments 473 15.1.13.3.1 Product approvals 473 15.1.14 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 474 15.1.14.1 Business overview 474 15.1.14.2 Products offered 474 15.1.14.3 Recent developments 475 15.1.14.3.1 Deals 475 15.1.15 ECKERT & ZIEGLER 476 15.1.15.1 Business overview 476 15.1.15.2 Products offered 477 15.1.15.3 Recent developments 478 15.1.15.3.1 Product approvals 478 15.1.15.3.2 Deals 478 15.1.15.3.3 Expansions 480 15.1.16 ISOTOPE JSC 481 15.1.16.1 Business overview 481 15.1.16.2 Products offered 481 15.1.16.3 Recent developments 482 15.1.16.3.1 Deals 482 15.1.16.3.2 Other developments 483 15.1.17 PDRADIOPHARMA INC. 484 15.1.17.1 Business overview 484 15.1.17.2 Products offered 484 15.1.17.3 Recent developments 486 15.1.17.3.1 Product launches & approvals 486 15.1.17.3.2 Deals 487 15.1.17.3.3 Expansions 487 15.1.18 ITM ISOTOPE TECHNOLOGIES MUNICH SE 488 15.1.18.1 Business overview 488 15.1.18.2 Products offered 489 15.1.18.3 Recent developments 489 15.1.18.3.1 Product approvals 489 15.1.18.3.2 Deals 490 15.1.18.3.3 Expansions 491 15.1.18.3.4 Other developments 492 15.1.19 NARODOWE CENTRUM BADAŃ JĄDROWYCH OŚRODEK RADIOIZOTOPÓW – POLATOM 493 15.1.19.1 Business overview 493 15.1.19.2 Products offered 494 15.1.19.3 Recent developments 496 15.1.19.3.1 Deals 496 15.1.20 ANSTO 497 15.1.20.1 Business overview 497 15.1.20.2 Products offered 498 15.1.20.3 Recent developments 499 15.1.20.3.1 Deals 499 15.1.20.3.2 Other developments 499 15.2 OTHER PLAYERS 500 15.2.1 SHINE TECHNOLOGIES, LLC 500 15.2.2 ISOTOPIA MOLECULAR IMAGING LTD. 501 15.2.3 INSTITUTE OF ISOTOPES 502 15.2.4 GLOBAL MEDICAL SOLUTIONS 504 15.2.5 ISOTEX DIAGNOSTICS 505 16 RESEARCH METHODOLOGY 506 16.1 RESEARCH DATA 506 16.2 RESEARCH APPROACH 506 16.2.1 SECONDARY RESEARCH 507 16.2.1.1 Key data from secondary sources 509 16.2.2 PRIMARY RESEARCH 509 16.2.2.1 Primary sources 510 16.2.2.2 Key data from primary sources 511 16.2.2.3 Breakdown of primaries 511 16.2.2.4 Insights from primary experts 512   16.3 RESEARCH METHODOLOGY DESIGN 512 16.4 MARKET SIZE ESTIMATION 514 16.4.1 APPROACH 1: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH – SUPPLY-SIDE ANALYSIS) 514 16.4.2 APPROACH 2: SECONDARY DATA & PRIMARY INTERVIEWS 517 16.4.3 APPROACH 3: SEGMENTAL MARKET SIZE ASSESSMENT 517 16.4.4 APPROACH 4: TOP-DOWN APPROACH 518 16.4.5 GROWTH FORECAST 518 16.4.6 GEOGRAPHIC MARKET ASSESSMENT (BY REGION AND COUNTRY) 520 16.5 MARKET BREAKDOWN & DATA TRIANGULATION 521 16.6 STUDY ASSUMPTIONS 522 16.7 RESEARCH LIMITATIONS 523 16.7.1 METHODOLOGY-RELATED LIMITATIONS 523 16.7.2 SCOPE-RELATED LIMITATIONS 523 16.8 RISK ASSESSMENT 523 17 APPENDIX 524 17.1 DISCUSSION GUIDE 524 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 532 17.3 CUSTOMIZATION OPTIONS 534 17.4 RELATED REPORTS 534 17.5 AUTHOR DETAILS 535

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 46 TABLE 2 MAIN MO-99 PRODUCTION REACTORS 63 TABLE 3 RADIOPHARMACEUTICALS: PHYSICAL HALF-LIFE AND MAJOR CLINICAL APPLICATIONS 64 TABLE 4 UK: NUCLEAR MEDICINE-RELATED WORKFORCE AND VACANCY DATA, 2021 72 TABLE 5 NUCLEAR MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 77 TABLE 6 NUCLEAR MEDICINE MARKET: ROLE IN ECOSYSTEM 84 TABLE 7 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024 85 TABLE 8 INDICATIVE PRICE OF NUCLEAR MEDICINE IN EASTERN EUROPE, BY TYPE, 2024 86 TABLE 9 INDICATIVE PRICE OF NUCLEAR MEDICINE IN MENAT REGION, BY TYPE, 2024 86 TABLE 10 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN INDIA, BY TYPE, 2024 87 TABLE 11 IMPORT VALUE FOR HS CODE 2844, 2020–2024 (USD THOUSAND) 87 TABLE 12 EXPORT VALUE FOR HS CODE 2844, 2020–2024 (USD THOUSAND) 88 TABLE 13 IMPORT VALUE FOR HS CODE 3002, 2020–2024 (USD THOUSAND) 89 TABLE 14 EXPORT VALUE FOR HS CODE 3002, 2020–2024 (USD THOUSAND) 89 TABLE 15 NUCLEAR MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026–2027 90 TABLE 16 CASE 1: BETA-AMYLOID PET/CT IMAGING ENABLES ALZHEIMER'S PATIENT QUALIFICATION FOR ANTI-AMYLOID THERAPY AT NEW YORK-PRESBYTERIAN HOSPITAL 93 TABLE 17 CASE 2: WHOLE-BODY PET/CT WITH EXTENDED AXIAL FOV ENABLES DETECTION OF RARE PERICARDIAL RECURRENCE IN PLEURAL MESOTHELIOMA AT RIGSHOSPITALET 93 TABLE 18 CASE 3: CLINICAL AND OPERATIONAL IMPACT OF IMPLEMENTING AN INTEGRATED THERANOSTICS PROGRAM IN BRAZIL 94 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 96 TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE MARKET 108 TABLE 21 NUCLEAR MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS 109 TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121 TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 122 TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124 TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125 TABLE 26 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126 TABLE 27 REGULATORY SCENARIO OF NORTH AMERICA 127 TABLE 28 REGULATORY SCENARIO OF EUROPE 130 TABLE 29 REGULATORY SCENARIO OF ASIA PACIFIC 133 TABLE 30 REGULATORY SCENARIO OF LATIN AMERICA 135 TABLE 31 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 135 TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 140 TABLE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS 141 TABLE 34 UNMET NEEDS IN NUCLEAR MEDICINE MARKET 143 TABLE 35 END-USER EXPECTATIONS IN NUCLEAR MEDICINE MARKET 144 TABLE 36 NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 37 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 148 TABLE 38 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 39 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES 149 TABLE 40 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023–2030 (USD MILLION) 151 TABLE 41 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 42 TC-99M MARKET, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 43 I-123 MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 44 TI-201 MARKET, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 45 GA-67 MARKET, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 46 OTHER SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 47 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 48 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 49 F-18 MARKET, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 50 RB-82 MARKET, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 51 OTHER PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 52 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 53 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 54 ALPHA EMITTERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 55 RA-223 MARKET, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 56 BETA EMITTERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 57 BETA EMITTERS MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 58 I-131 MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 59 Y-90 MARKET, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 60 SM-153 MARKET, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 61 LU-177 MARKET, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 62 OTHER BETA EMITTERS MARKET, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 63 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 64 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 65 I-125 MARKET, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 66 IR-192 MARKET, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 67 PD-103 MARKET, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 68 CS-131 MARKET, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 69 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 70 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 71 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 72 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 73 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 74 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 75 NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 76 NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 77 NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 78 NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 79 NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 80 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 81 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 82 NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 83 NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 84 NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 85 NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 86 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 87 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 88 NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 89 NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 90 NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 91 NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 92 NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 93 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2023–2030 (THOUSAND PROCEDURES) 196 TABLE 94 NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (THOUSAND PROCEDURES) 196 TABLE 95 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2023–2030 (THOUSAND PROCEDURES) 197 TABLE 96 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2023–2030 (THOUSAND PROCEDURES) 198 TABLE 97 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2023–2030 (THOUSAND PROCEDURES) 199 TABLE 98 NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 99 NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 203 TABLE 100 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 101 NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 102 NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 103 NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 104 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 211 TABLE 105 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 106 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 107 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 108 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 109 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 110 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 111 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 112 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 113 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 215 TABLE 114 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 115 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 116 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 117 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 118 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 218 TABLE 119 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 220 TABLE 120 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 121 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 122 US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 123 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 124 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 125 US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 126 US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 127 US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 128 US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 129 US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 130 US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 131 US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 132 US: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 133 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 227 TABLE 134 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 135 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 136 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 137 CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 138 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 139 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 140 CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 141 CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 142 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 143 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 144 CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 145 CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 146 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 233 TABLE 147 EUROPE: KEY MACROECONOMIC INDICATORS 235 TABLE 148 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 149 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 150 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 151 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 152 EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 153 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 154 EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 155 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 156 EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 157 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 158 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 159 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 160 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 161 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 162 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 163 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 164 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 165 GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 166 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 167 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 168 GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 169 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 170 GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 171 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 172 GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 173 GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 174 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 249 TABLE 175 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 251 TABLE 176 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 177 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 178 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 179 FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 180 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 181 FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 182 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 183 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 184 FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 185 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 186 FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 187 FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 188 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 189 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 190 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 191 UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 192 UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 193 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 194 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 195 UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 196 UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 197 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 198 UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 199 UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 200 UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 201 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 202 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 266 TABLE 203 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 204 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 205 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 206 ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 207 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 208 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 209 ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 210 ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270 TABLE 211 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 212 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 213 ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 214 ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 215 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 216 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 217 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 218 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 219 SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 220 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 221 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 222 SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 223 SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 224 SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 225 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 226 SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 227 SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 228 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 229 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 230 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 231 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 232 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 233 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 234 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 235 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 236 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 237 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 238 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 239 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 240 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 241 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 242 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 289 TABLE 243 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 291 TABLE 244 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 245 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 246 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 247 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 248 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 249 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 250 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 251 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 252 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 253 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 254 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 255 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 256 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 297 TABLE 257 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 258 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 259 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 260 JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 261 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 262 JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 263 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 264 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 303 TABLE 265 JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 266 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 267 JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 268 JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 269 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 305 TABLE 270 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 307 TABLE 271 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 272 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 273 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 274 CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 275 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 276 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 277 CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 278 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 311 TABLE 279 CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 280 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 281 CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 282 CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 283 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 313 TABLE 284 INDIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 285 INDIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 286 INDIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 287 INDIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 288 INDIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 289 INDIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 290 INDIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 291 INDIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 318 TABLE 292 INDIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 293 INDIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 294 INDIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 295 INDIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 296 INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 321 TABLE 297 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 298 SOUTH KOREA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 299 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 300 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 301 SOUTH KOREA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 302 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 303 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 304 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 325 TABLE 305 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 306 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 307 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 308 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 309 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 328 TABLE 310 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 311 AUSTRALIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 312 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 313 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 314 AUSTRALIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 315 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 316 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 317 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 332 TABLE 318 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 333 TABLE 319 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 333 TABLE 320 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 321 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 322 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 335 TABLE 323 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 324 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 325 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 326 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 338 TABLE 328 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 338 TABLE 329 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 330 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 339 TABLE 331 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 332 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 333 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 334 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 335 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 342 TABLE 336 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 343 TABLE 337 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 343 TABLE 338 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 343 TABLE 339 LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 340 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 341 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 342 LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 343 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 344 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 345 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 347 TABLE 346 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 347 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 348 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 349 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 350 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 349 TABLE 351 BRAZIL: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 352 BRAZIL: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 353 BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 354 BRAZIL: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 355 BRAZIL: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 356 BRAZIL: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 357 BRAZIL: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 353 TABLE 358 BRAZIL: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 353 TABLE 359 BRAZIL: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 353 TABLE 360 BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 354 TABLE 361 BRAZIL: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 354 TABLE 362 BRAZIL: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 355 TABLE 363 BRAZIL: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 355 TABLE 364 MEXICO: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 365 MEXICO: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 366 MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 367 MEXICO: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 358 TABLE 368 MEXICO: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 358 TABLE 369 MEXICO: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 359 TABLE 370 MEXICO: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 359 TABLE 371 MEXICO: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 360 TABLE 372 MEXICO: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 360 TABLE 373 MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 360 TABLE 374 MEXICO: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 375 MEXICO: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 376 MEXICO: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 362 TABLE 377 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 363 TABLE 378 REST OF LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 363 TABLE 379 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 363 TABLE 380 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 364 TABLE 381 REST OF LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 364 TABLE 382 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 365 TABLE 383 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 365 TABLE 384 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 366 TABLE 385 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 386 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 387 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 388 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 389 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 368 TABLE 390 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 369 TABLE 391 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 369 TABLE 392 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 370 TABLE 393 MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 370 TABLE 394 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 370 TABLE 395 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 396 MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 397 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 398 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 399 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 372 TABLE 400 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 401 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 373 TABLE 402 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 373 TABLE 403 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 374 TABLE 404 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 374 TABLE 405 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 375 TABLE 406 GCC COUNTRIES: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 407 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 408 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 409 GCC COUNTRIES: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 410 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 411 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 378 TABLE 412 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 378 TABLE 413 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 378 TABLE 414 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 379 TABLE 415 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 379 TABLE 416 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 380 TABLE 417 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 380 TABLE 418 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 419 REST OF MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 420 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 421 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 422 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 423 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION) 383 TABLE 424 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION) 383 TABLE 425 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 384 TABLE 426 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 384 TABLE 427 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 384 TABLE 428 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 385 TABLE 429 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 385 TABLE 430 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION) 386 TABLE 431 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE, JANUARY 2022–DECEMBER 2025 388 TABLE 432 NUCLEAR MEDICINE MARKET: DEGREE OF COMPETITION 393 TABLE 433 NUCLEAR MEDICINE MARKET: REGION FOOTPRINT 401 TABLE 434 NUCLEAR MEDICINE MARKET: TYPE FOOTPRINT 402 TABLE 435 NUCLEAR MEDICINE MARKET: APPLICATION FOOTPRINT 403 TABLE 436 NUCLEAR MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 406 TABLE 437 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 406 TABLE 438 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY TYPE 407 TABLE 439 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY APPLICATION 408 TABLE 440 NUCLEAR MEDICINE MARKET: PRODUCT APPROVALS, JANUARY 2022– DECEMBER 2025 408 TABLE 441 NUCLEAR MEDICINE MARKET: DEALS, JANUARY 2022–DECEMBER 2025 410 TABLE 442 NUCLEAR MEDICINE MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025 412 TABLE 443 NUCLEAR MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 413 TABLE 444 NOVARTIS AG: COMPANY OVERVIEW 414 TABLE 445 NOVARTIS AG: PRODUCTS OFFERED 415 TABLE 446 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 416 TABLE 447 NOVARTIS AG: DEALS, JANUARY 2022–DECEMBER 2025 417 TABLE 448 NOVARTIS AG: EXPANSIONS, JANUARY 2022–DECEMBER 2025 418 TABLE 449 LANTHEUS HOLDINGS, INC.: COMPANY OVERVIEW 421 TABLE 450 LANTHEUS HOLDINGS, INC.: PRODUCTS OFFERED 422 TABLE 451 LANTHEUS HOLDINGS, INC.: DEALS, JANUARY 2022–DECEMBER 2025 423 TABLE 452 GE HEALTHCARE: COMPANY OVERVIEW 425 TABLE 453 GE HEALTHCARE: PRODUCTS OFFERED 426 TABLE 454 GE HEALTHCARE: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 427 TABLE 455 GE HEALTHCARE: DEALS, JANUARY 2022–DECEMBER 2025 427 TABLE 456 GE HEALTHCARE: EXPANSIONS, JANUARY 2022–DECEMBER 2025 429 TABLE 457 GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 429 TABLE 458 CURIUM: COMPANY OVERVIEW 431 TABLE 459 CURIUM: PRODUCTS OFFERED 431 TABLE 460 CURIUM: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2022–DECEMBER 2025 435 TABLE 461 CURIUM: DEALS, JANUARY 2022–DECEMBER 2025 436 TABLE 462 CURIUM: EXPANSIONS, JANUARY 2022–DECEMBER 2025 438 TABLE 463 CURIUM: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 438 TABLE 464 TELIX PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 440 TABLE 465 TELIX PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 441 TABLE 466 TELIX PHARMACEUTICALS LIMITED: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 442 TABLE 467 TELIX PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022–DECEMBER 2025 443 TABLE 468 TELIX PHARMACEUTICALS LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 444 TABLE 469 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 446 TABLE 470 SIEMENS HEALTHINEERS: PRODUCTS OFFERED 447 TABLE 471 SIEMENS HEALTHINEERS: DEALS, JANUARY 2022–DECEMBER 2025 448 TABLE 472 SIEMENS HEALTHINEERS: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 448 TABLE 473 CHINA ISOTOPE & RADIATION CORPORATION: COMPANY OVERVIEW 449 TABLE 474 CHINA ISOTOPE & RADIATION CORPORATION: PRODUCTS OFFERED 450 TABLE 475 CHINA ISOTOPE & RADIATION CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 451 TABLE 476 BAYER AG: COMPANY OVERVIEW 452 TABLE 477 BAYER AG: PRODUCTS OFFERED 453 TABLE 478 BAYER AG: DEALS, JANUARY 2022–DECEMBER 2025 454 TABLE 479 BRACCO IMAGING S.P.A.: COMPANY OVERVIEW 455 TABLE 480 BRACCO IMAGING S.P.A.: PRODUCTS OFFERED 455 TABLE 481 BRACCO IMAGING S.P.A.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 456 TABLE 482 BRACCO IMAGING S.P.A.: DEALS, JANUARY 2022–DECEMBER 2025 456 TABLE 483 BRACCO IMAGING S.P.A.: OTHER DEVELEOPMENTS, JANUARY 2022–DECEMBER 2025 457 TABLE 484 CARDINAL HEALTH: COMPANY OVERVIEW 458 TABLE 485 CARDINAL HEALTH: PRODUCTS OFFERED 459 TABLE 486 CARDINAL HEALTH: DEALS, JANUARY 2022–DECEMBER 2025 462 TABLE 487 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW 463 TABLE 488 JUBILANT PHARMOVA LIMITED: PRODUCTS OFFERED 464 TABLE 489 JUBILANT PHARMOVA LIMITED: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 466 TABLE 490 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2022–DECEMBER 2025 466 TABLE 491 JUBILANT PHARMOVA LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 467 TABLE 492 ELI LILLY AND COMPANY: COMPANY OVERVIEW 468 TABLE 493 ELI LILLY AND COMPANY: PRODUCTS OFFERED 469 TABLE 494 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–DECEMBER 2025 470 TABLE 495 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 471 TABLE 496 BWXT MEDICAL LTD.: COMPANY OVERVIEW 472 TABLE 497 BWXT MEDICAL LTD.: PRODUCTS OFFERED 472 TABLE 498 BWXT MEDICAL LTD.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 473 TABLE 499 NTP RADIOISOTOPES SOC LTD.: COMPANY OVERVIEW 474 TABLE 500 NTP RADIOISOTOPES SOC LTD.: PRODUCTS OFFERED 474 TABLE 501 NTP RADIOISOTOPES SOC LTD.: DEALS, JANUARY 2022–DECEMBER 2025 475 TABLE 502 ECKERT & ZIEGLER: COMPANY OVERVIEW 476 TABLE 503 ECKERT & ZIEGLER: PRODUCTS OFFERED 477 TABLE 504 ECKERT & ZIEGLER: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 478 TABLE 505 ECKERT & ZIEGLER: DEALS, JANUARY 2022–DECEMBER 2025 478 TABLE 506 ECKERT & ZIEGLER: EXPANSIONS, JANUARY 2022–DECEMBER 2025 480 TABLE 507 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): COMPANY OVERVIEW 481 TABLE 508 ISOTOPE JSC: PRODUCTS OFFERED 481 TABLE 509 ISOTOPE JSC: DEALS, JANUARY 2022–DECEMBER 2025 482 TABLE 510 ISOTOPE JSC: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 483 TABLE 511 PDRADIOPHARMA INC.: COMPANY OVERVIEW 484 TABLE 512 PDRADIOPHARMA INC.: PRODUCTS OFFERED 484 TABLE 513 PDRADIOPHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–DECEMBER 2025 486 TABLE 514 PDRADIOPHARMA INC.: DEALS, JANUARY 2022–DECEMBER 2025 487 TABLE 515 PDRADIOPHARMA INC.: EXPANSIONS, JANUARY 2022–DECEMBER 2025 487 TABLE 516 ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY OVERVIEW 488 TABLE 517 ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCTS OFFERED 489 TABLE 518 ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 489 TABLE 519 ITM ISOTOPE TECHNOLOGIES MUNICH SE: DEALS, JANUARY 2022–DECEMBER 2025 490 TABLE 520 ITM ISOTOPE TECHNOLOGIES MUNICH SE: EXPANSIONS, JANUARY 2022–DECEMBER 2025 491 TABLE 521 ITM ISOTOPE TECHNOLOGIES MUNICH SE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 492 TABLE 522 NARODOWE CENTRUM BADAŃ JĄDROWYCH OŚRODEK RADIOIZOTOPÓW – POLATOM: COMPANY OVERVIEW 493 TABLE 523 NARODOWE CENTRUM BADAŃ JĄDROWYCH OŚRODEK RADIOIZOTOPÓW – POLATOM: PRODUCTS OFFERED 494 TABLE 524 NARODOWE CENTRUM BADAŃ JĄDROWYCH OŚRODEK RADIOIZOTOPÓW – POLATOM: DEALS, JANUARY 2022–DECEMBER 2025 496 TABLE 525 ANSTO: COMPANY OVERVIEW 497 TABLE 526 ANSTO: PRODUCTS OFFERED 498 TABLE 527 ANSTO: DEALS, JANUARY 2022–DECEMBER 2025 499 TABLE 528 ANSTO: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 499 TABLE 529 RISK ASSESSMENT: NUCLEAR MEDICINE MARKET 523 FIGURE 1 NUCLEAR MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE 42 FIGURE 2 MARKET SCENARIO 50 FIGURE 3 GLOBAL NUCLEAR MEDICINE MARKET, 2023–2030 50 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2022–2025 51 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF NUCLEAR MEDICINE MARKET 52 FIGURE 6 HIGH-GROWTH SEGMENTS IN NUCLEAR MEDICINE MARKET, 2025–2030 53 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NUCLEAR MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 54 FIGURE 8 RAPID EXPANSION OF RADIOLIGAND AND TARGETED RADIONUCLIDE THERAPY TO DRIVE MARKET GROWTH 55 FIGURE 9 DIAGNOSTIC NUCLEAR MEDICINE MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024 56 FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 56 FIGURE 11 GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD 57 FIGURE 12 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59 FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN EMERGING ECONOMIES, 2022–2050 70 FIGURE 14 NUCLEAR MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 76 FIGURE 15 GLOBAL GDP GROWTH, 2020–2030 79 FIGURE 16 NUCLEAR MEDICINE MARKET: VALUE CHAIN ANALYSIS (2024) 81 FIGURE 17 NUCLEAR MEDICINE MARKET: ECOSYSTEM ANALYSIS 83 FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 FIGURE 20 PATENT APPLICATION TRENDS IN NUCLEAR MEDICINE MARKET, 2015–2026 107 FIGURE 21 JURISDICTION & TOP APPLICANT ANALYSIS FOR NUCLEAR MEDICINE MARKET 107 FIGURE 22 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE MARKET (JANUARY 2015–FEBRUARY 2026) 108 FIGURE 23 MARKET POTENTIAL OF AI/GEN AI ON NUCLEAR MEDICINE ACROSS END USERS 113 FIGURE 24 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 116 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 139 FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 141 FIGURE 27 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT 211 FIGURE 28 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2024) 290 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2020–2024 392 FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2024 393 FIGURE 31 NUCLEAR MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 396 FIGURE 32 EV/EBITDA OF KEY VENDORS 397 FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 397 FIGURE 34 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 399 FIGURE 35 NUCLEAR MEDICINE MARKET: COMPANY FOOTPRINT 400 FIGURE 36 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 405 FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT (2024) 415 FIGURE 38 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2024) 422 FIGURE 39 GE HEALTHCARE: COMPANY SNAPSHOT (2024) 426 FIGURE 40 TELIX PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024) 441 FIGURE 41 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2024) 447 FIGURE 42 CHINA ISOTOPE & RADIATION CORPORATION: COMPANY SNAPSHOT (2024) 450 FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024) 453 FIGURE 44 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 459 FIGURE 45 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2024) 464 FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024) 469 FIGURE 47 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2024) 477 FIGURE 48 ANSTO: COMPANY SNAPSHOT (2024) 497 FIGURE 49 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET 506 FIGURE 50 RESEARCH DESIGN 507 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 511 FIGURE 52 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 513 FIGURE 53 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 515 FIGURE 54 NUCLEAR MEDICINE MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION 515 FIGURE 55 NUCLEAR MEDICINE MARKET: REVENUE ANALYSIS OF TOP FOUR COMPANIES (2024) 516 FIGURE 56 NUCLEAR MEDICINE MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 517 FIGURE 57 NUCLEAR MEDICINE MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 518 FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN NUCLEAR MEDICINE INDUSTRY 519 FIGURE 59 CAGR PROJECTIONS: NUCLEAR MEDICINE MARKET, 2025−2030 520 FIGURE 60 DATA TRIANGULATION METHODOLOGY 521